<PAGE>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 10-Q

                                   (MARK ONE)

             [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
                   OF THE SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended September 30, 2001

                                       OR

             [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


                         COMMISSION FILE NUMBER 0-19635


                               GENTA INCORPORATED
   (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CERTIFICATE OF INCORPORATION)

                Delaware                                      33-0326866
     (STATE OR OTHER JURISDICTION OF                        (I.R.S. EMPLOYER
     INCORPORATION OR ORGANIZATION)                       IDENTIFICATION NUMBER)


             Two Oak Way
      Berkeley Heights, New Jersey                                07922
 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)                       (ZIP CODE)

                                 (908) 286-9800
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

         Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                 Yes        X                 No
                          ------                  ------


          As of November 5, 2001, the registrant had 63,151,057 shares
                          of common stock outstanding.

================================================================================

<PAGE>


                               GENTA INCORPORATED
                               INDEX TO FORM 10-Q


<TABLE>
<CAPTION>
                                                                                                  Page
                                                                                                  ----
<S>                                                                                               <C>
PART I.    FINANCIAL INFORMATION

Item 1.    Financial Statements

           Condensed Consolidated Balance Sheets at September 30, 2001 (Unaudited)
              and December 31, 2000                                                                 3

           Condensed Consolidated Statements of Operations for the
              Three and Nine Months Ended September 30, 2001 and 2000 (Unaudited)                   4

           Condensed Consolidated Statements of Cash Flows for the
              Nine Months Ended September 30, 2001 and 2000 (Unaudited)                             5

           Notes to Condensed Consolidated Financial Statements (Unaudited)                         6

Item 2.    Management's Discussion and Analysis of Financial Condition
              and Results of Operations                                                            11

Item 3.    Quantitative and Qualitative Disclosures about Market Risk                              20


PART II.   OTHER INFORMATION

Item 1.    Legal Proceedings                                                                       21

Item 4.    Submission of Matters to a Vote of Security Holders                                     22

Item 6.    Exhibits and Reports on Form 8-K                                                        22


SIGNATURES                                                                                         23
</TABLE>

<PAGE>

                               GENTA INCORPORATED
                     CONDENSED CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                              SEPTEMBER 30,      DECEMBER 31,
(In thousands, except per share data)                                             2001               2000
                                                                              -------------      ------------
                                                                                (UNAUDITED)
<S>                                                                               <C>              <C>
                                              ASSETS
Current assets:
   Cash and cash equivalents..............................................        $18,383          $19,025
   Short-term investments.................................................         15,786           31,174
   Accounts receivable....................................................              8               --
   Notes receivable.......................................................            200            1,338
   Other current assets...................................................          1,223              425
                                                                                  -------          -------
Total current assets......................................................         35,600          $51,962

Property and equipment, net...............................................          1,231              758
Intangibles, net .........................................................          2,324            2,923
Other assets..............................................................          1,620            1,565
                                                                                  -------          -------
Total assets .............................................................        $40,775          $57,208
                                                                                  =======          =======

                               LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
   Accounts payable ......................................................        $ 3,877          $   614
   Accrued expenses.......................................................          3,550            2,452
   Other current liabilities..............................................            595              575
                                                                                  -------          -------
Total current liabilities.................................................          8,022            3,641
                                                                                  -------          -------
   Deferred revenues, long-term...........................................             75               --
                                                                                  -------          -------
Stockholders' equity:
   Preferred stock, Series A convertible preferred stock, $.001
      par value; 5,000 shares authorized, 261 shares issued and
      outstanding at September 30, 2001 and December 31, 2000,
      respectively; liquidation value of $13,060..........................             --               --
   Common stock, $.001 par value; 95,000 shares authorized,
      63,060 and 51,085 shares issued and outstanding at
      September 30, 2001 and December 31, 2000, respectively..............             63               51
   Additional paid-in capital ............................................        214,438          206,452
   Accumulated deficit ...................................................       (180,731)        (151,949)
   Deferred compensation .................................................         (1,078)          (1,082)
   Accumulated other comprehensive (loss) income..........................            (14)              95
                                                                                  -------          -------

Total stockholders' equity ...............................................         32,678           53,567
                                                                                  -------          -------

Total liabilities and stockholders' equity................................        $40,775          $57,208
                                                                                  =======          =======
</TABLE>

     See accompanying notes to condensed consolidated financial statements.

                                       3



<PAGE>


                               GENTA INCORPORATED
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                          THREE MONTHS ENDED SEPTEMBER 30,      NINE MONTHS ENDED SEPTEMBER 30,
                                                          --------------------------------      -------------------------------
(In thousands, except per share data)                           2001              2000              2001               2000
                                                              --------          -------            --------          --------
<S>                                                           <C>               <C>                <C>               <C>
Revenues:
   License fees ......................................        $     22          $    17            $     92          $     17
   Royalty fees ......................................               1               --                  13                --
                                                              --------          -------            --------          --------
                                                                    23               17                 105                17
                                                              --------          -------            --------          --------
Costs and expenses:
   Research and development ..........................           9,150            1,360              23,786             3,914
   General and administrative ........................           2,060              897               5,582             2,727
   Promega settlement ................................              --               --               1,000                --
   Compensation expense related to stock options .....             186              256                 580             8,313
                                                              --------          -------            --------          --------
                                                                11,396            2,513              30,948            14,954
                                                              --------          -------            --------          --------
Loss from operations .................................         (11,373)          (2,496)            (30,843)          (14,937)

Equity in net income of joint venture ................              --               --                  --               502
Other income, principally net interest income ........             953              192               2,061               455
                                                              --------          -------            --------          --------
Net loss .............................................         (10,420)          (2,304)            (28,782)          (13,980)
Preferred stock dividends ............................              --               --                  --            (3,443)
                                                              --------          -------            --------          --------
Net loss applicable to common shares .................        $(10,420)         $(2,304)           $(28,782)         $(17,423)
                                                              ========          =======            ========          ========

Net loss per common share ............................        $  (0.19)         $ (0.05)           $  (0.54)         $  (0.50)
                                                              ========          =======            ========          ========

Shares used in computing net loss per common share ...          54,735           44,168              52,988            35,164
                                                              ========          =======            ========          ========
</TABLE>



     See accompanying notes to condensed consolidated financial statements.

                                       4

<PAGE>


                               GENTA INCORPORATED
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)


<TABLE>
<CAPTION>
                                                                            NINE MONTHS ENDED SEPTEMBER 30,
                                                                            -------------------------------
(In thousands)                                                                     2001            2000
                                                                                ---------        --------
<S>                                                                             <C>             <C>
OPERATING ACTIVITIES
Net loss .............................................................          $(28,782)       $(13,980)
Items reflected in net loss not requiring cash:
   Depreciation and amortization .....................................               802             368
   Loss on disposal of fixed assets ..................................                15              --
   Loss on Promega settlement ........................................             1,000              --
   Compensation expense related to stock options .....................               580           8,313
Changes in operating assets and liabilities ..........................             3,523            (251)
                                                                                --------        --------
Net cash used in operating activities ................................           (22,862)         (5,550)
                                                                                --------        --------

INVESTING ACTIVITIES
  Purchase of available-for-sale short-term investments ..............           (11,304)         (2,296)
  Maturities and sales of available-for-sale short-term investments ..            26,792           2,296
  Purchase of property and equipment .................................              (690)           (170)
  Principal payments received on notes receivable ....................                --              80
  Purchase of intangibles ............................................                --            (400)
                                                                                --------        --------
Net cash provided by (used in) investing activities ..................            14,798            (490)
                                                                                --------        --------
FINANCING ACTIVITIES
  Issuance of common stock upon exercise of warrants and options .....             7,422           2,857
  Proceeds from issuance of common stock for private placement,
   net ...............................................................                --          13,656
                                                                                --------        --------
Net cash provided by financing activities ............................             7,422          16,513
                                                                                --------        --------
(Decrease) increase in cash and cash equivalents .....................              (642)         10,473

Cash and cash equivalents at beginning of period .....................            19,025          10,101
                                                                                --------        --------
Cash and cash equivalents at end of period ...........................          $ 18,383        $ 20,574
                                                                                ========        ========
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid ........................................................          $     --        $     15

SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND
  FINANCING ACTIVITIES:
Market value change of available-for-sale equity securities ..........                (3)             --
Market value change of available-for-sale short-term investments .....               (45)             --
Common stock issued in payment of hiring bonus .......................                50              --
Common stock issued in payment of dividends on preferred stock .......                --             953
Common stock issued in payment of patent portfolios ..................                --           2,484
Preferred stock dividends accrued ....................................                --           3,443
Income receivable for exercise of warrants ...........................                --           5,151
Stock warrants issued to placement agent .............................                --             867
</TABLE>



     See accompanying notes to condensed consolidated financial statements.

                                       5


<PAGE>


                               GENTA INCORPORATED
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2001
                                   (UNAUDITED)


(1)      BASIS OF PRESENTATION

         The unaudited condensed consolidated financial statements of Genta
Incorporated, a Delaware corporation ("Genta" or the "Company"), presented
herein have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and
with the instructions to Form 10-Q. Accordingly, they do not include all of the
information and note disclosures required to be presented for complete financial
statements. The accompanying financial statements reflect all adjustments
(consisting only of normal recurring accruals), which are, in the opinion of
management, necessary for a fair presentation of the results for the interim
periods presented.

         The unaudited condensed consolidated financial statements and related
disclosures have been prepared with the presumption that users of the interim
financial information have read or have access to the audited financial
statements for the preceding fiscal year. Accordingly, these financial
statements should be read in conjunction with the audited consolidated financial
statements and the related notes thereto included in the Company's Annual Report
on Form 10-K for the year ended December 31, 2000 (the "2000 Form 10-K").

         The Company has experienced significant quarterly fluctuations in
operating results and it expects that these fluctuations will continue.

         Net Loss Per Common Share

         Basic and diluted loss per common share are identical for the three and
nine months ended September 30, 2000 and 2001 as potentially dilutive
securities, including options, warrants and convertible preferred stock have
been excluded in the calculation of the net loss per common share due to their
anti-dilutive effect.

         Recent Accounting Pronouncements

         The Company implemented Statement of Financial Accounting Standards 133
"Accounting for Derivative Instruments and Hedging Activities," as amended, on
January 1, 2001 and did not have any derivative instruments that resulted in a
transition adjustment.

         In June 2001, the Financial Accounting Standards Board ("FASB")
approved for issuance Statement of Financial Accounting Standards 141 ("SFAS
141"), "Business Combinations". SFAS 141 eliminated the pooling method of
accounting for business combinations initiated after June 30, 2001. The Company
has adopted the provisions of SFAS 141 as of the effective date but does not
expect SFAS 141 to have a material effect on the Company's financial position or
results of operations.

         In July 2001, the FASB issued Statement of Financial Accounting
Standards 142 ("SFAS 142"), "Goodwill and Other Intangible Assets". SFAS 142
requires periodic evaluation of goodwill and indefinite lived intangible assets
for impairment and discontinues amortization of such intangibles. SFAS 142 will
be effective for fiscal years beginning after December 15, 2001 and the Company
intends to adopt the provisions of SFAS 142 as of the effective date. The impact
of this pronouncement on the Company's financial position and results of
operations is currently being evaluated.

         In August 2001, the FASB issued Statement of Financial Accounting
Standards 143 ("SFAS 143"), "Accounting for Asset Retirement Obligations". SFAS
143 requires that the liability for an asset retirement obligation should be
recognized at its fair market value when these liabilities are incurred. SFAS
143 will be effective for fiscal years beginning after June 15, 2002 and the
Company intends to adopt the provisions of SFAS 143 as of the effective date but
does not expect SFAS 143 to have a material effect on the Company's financial
position or results of operations.


                                       6

<PAGE>
         In October 2001, the FASB issued Statement of Financial Accounting
Standards 144 ("SFAS 144"), "Accounting for the Impairment or Disposal of
Long-Lived Assets". SFAS 144 requires that one accounting model be used for
long-lived assets to be disposed of by sale whether previously held and used or
newly acquired, and by broadening the presentation of discontinued operations to
include more disposal transactions. SFAS 144 will be effective for fiscal years
beginning after December 15, 2001 and the Company intends to adopt the
provisions of SFAS 144 as of the effective date but does not expect SFAS 144 to
have a material effect on the Company's financial position or results of
operations.

(2)      DISCONTINUED OPERATIONS

         On March 19, 1999, the Company entered into an agreement (the "JBL
Agreement") with Promega Corporation ("Promega") whereby a wholly-owned
subsidiary of Promega acquired substantially all of the assets and assumed
certain liabilities of JBL Scientific, Inc. ("JBL"), a Genta wholly-owned
subsidiary. Consideration for this transaction consisted of approximately $4.8
million in cash, a 7% promissory note for $1.2 million, and certain
pharmaceutical development services in support of the Company's development
activities. The transaction was completed on May 10, 1999 and the Company
recognized $1.6 million as gain on sale of discontinued operations.

         During May 2000, Promega notified Genta regarding two claims against
Genta and its wholly-owned subsidiary, Genko Scientific, Inc. (f/k/a JBL
Scientific, Inc.) ("Genko"), for indemnifiable damages in the aggregate amount
of $2.82 million under the JBL Agreement. Promega announced that it intended to
offset against the principal amount due under its $1.2 million promissory note
issued as partial consideration for the Genko assets, which note provided for
payment of $.7 million on June 30, 2000. Promega further demanded an additional
$1.62 million in settlement of this matter. Genta believed that Promega's claims
were without merit and, accordingly, on October 16, 2000, Genta filed suit in
the US District Court of California for nonpayment on the $1.2 million
promissory note plus accrued interest. On November 6, 2000, Promega filed a
counter suit against the Company in the US District Court of California for the
indemnifiable damages discussed above. During the first quarter of 2001, the
Company agreed to resolve the matter with Promega, and, in connection therewith,
agreed to restructure its $1.2 million promissory note receivable to provide for
a $.2 million non-interest bearing note due upon final resolution of certain
environmental issues related to JBL as more fully discussed in Note 8, and
forgive all accrued interest. The transaction resulted in a non-recurring charge
of $1.0 million for the quarter ended March 31, 2001.

         In connection with the JBL Agreement, .25 million stock options to
purchase Genta common stock (the "Options") were granted to the former employees
of JBL pursuant to an ongoing service arrangement between Promega and the
Company. The Options were accounted for pursuant to guidelines in Statement of
Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation," and EITF 96-18 using the Black-Scholes option pricing model, and
had an exercise price of $2.03 per share, a one-year vesting period and an
expiration date two years after the date of grant. The estimated fair value of
the Options was based on services provided and aggregated $1.7 million as of
September 30, 2000. Fluctuations in the market price of the common stock
underlying the Options, amortized over the vesting period, resulted in a charge
of $.948 million to compensation expense related to stock options for the nine
months ended September 30, 2000. The Options were fully vested on May 9, 2000
and, accordingly, no additional compensation expense related to stock options
has been recognized for the nine months ended September 30, 2001.



                                       7

<PAGE>
(3)      Short-Term Investments

         All corporate debt securities at September 30, 2001, mature within one
year or less. Information in the aggregate with respect to these investments is
presented below (in thousands):

                             Gross             Gross
        Amortized          unrealized        unrealized         Estimated
          costs              gains             losses          fair value
        ---------          ----------        ----------        ----------

         $ 15,800             $ 62              $ 76            $ 15,786
         ========             ====              ====            ========

(4)      DEFERRED REVENUES

         In July 2001, the Company entered into a non-exclusive license
agreement which included an up front cash payment of $.1 million along with
royalty payments on product sales. This license agreement expires in July 2006.
The Company will recognize license fee revenue for the up-front payment over the
term of the agreement in accordance with Staff Accounting Bulletin No. 101.

(5)      EQUITY IN NET INCOME OF JOINT VENTURE (GENTA JAGO)

         Genta Jago Technologies B.V. ("Genta Jago") is a joint venture formed
by Skyepharma PLC and Genta. On March 4, 1999, SkyePharma PLC (on behalf of
itself and its affiliates) entered into an interim agreement with Genta (the
"Interim JV Agreement") pursuant to which the parties to the joint venture
released each other from all liability relating to unpaid development costs and
funding obligations of Genta Jago. Under the terms of the Interim JV Agreement,
SkyePharma PLC assumed responsibility for substantially all the obligations of
the joint venture to third parties as well as further development of the product
line. Pursuant to the terms of the agreement, earnings of the joint venture are
to be allocated equally between the two parties. Accordingly, Genta recognized
$.502 million as its equity in net income of the joint venture during the first
quarter of 2000. Since the first quarter of 2000, there have been no earnings or
losses of the joint venture to be allocated between the two parties.

(6)      COMPREHENSIVE LOSS

         The following sets forth the calculation of comprehensive loss for the
respective periods presented below:

<TABLE>
<CAPTION>
(In thousands)                         Three Months Ended September 30,          Nine Months Ended September 30,
                                       --------------------------------          -------------------------------
                                           2001                2000                  2001                 2000
                                         --------            -------               --------             --------
<S>                                      <C>                 <C>                   <C>                  <C>
Net loss ..........................      $(10,420)           $(2,304)              $(28,782)            $(13,980)
Unrealized loss on market value
change on available-for-sale
short-term investments ............          (139)                --                   (109)                  --
                                         --------            -------               --------             --------
Total comprehensive loss ..........      $(10,559)           $(2,304)              $(28,891)            $(13,980)
                                         ========            =======               ========             ========
</TABLE>

(7)      RELATED PARTY TRANSACTIONS

         In September 2001, the Company received approximately $3.4 million from
certain affiliates, Aries Select I, LLC, Aries Select II, LLC, and Aries Select,
LTD, upon the conversion of warrants into approximately 8.8 million shares of
common stock.



                                       8


<PAGE>

(8)      COMMITMENTS AND CONTINGENCIES

         LITIGATION

         In October 1996, JBL retained a chemical consulting firm to advise it
with respect to an incident of soil and groundwater contamination (the "Spill").
Sampling conducted at the JBL facility revealed the presence of chloroform and
perchloroethylenes ("PCEs") in the soil and groundwater at this site. A
semi-annual groundwater-monitoring program is being conducted under the
supervision of the California Regional Water Quality Control Board ("the Water
Board") for the purpose of determining whether the levels of chloroform and PCEs
have decreased over time. In April 2001, the Company requested closure of this
matter from the Water Board as the current sampling results indicated that PCEs
and chloroform have decreased in all of the monitoring sites. The Water Board
has instructed the Company to remove these monitoring wells, which is the last
step before final site closure. The Company is currently in the process of
having these monitoring wells removed. The Company has agreed to indemnify
Promega with respect to this matter and, in the opinion of management, has
adequately accrued to cover remedial expenses as of September 30, 2001.
Management also believes that any residual expense stemming from further
investigation or remediation of this matter will not have a material adverse
effect on the business of the Company, although there can be no assurance
thereof.

         JBL received notice on October 16, 1998 from Region IX of the
Environmental Protection Agency (the "EPA") that it had been identified as a
potentially responsible party ("PRP") at the Casmalia Disposal Site located in
Santa Barbara, California. The EPA has designated JBL as a de minimis PRP and
the Company expects to receive a revised settlement proposal from the EPA later
this year. While the terms of the EPA settlement have not been finalized,
management believes that such terms shall provide for standard contribution
protection and release provisions. The Company has agreed to indemnify Promega
with respect to this matter and management believes that any residual expense
stemming from further investigation or remediation of this matter will not have
a material adverse effect on the business of the Company, although there can be
no assurance thereof.

         During 1995, Genta Pharmaceuticals Europe S.A. ("Genta Europe"), a
wholly-owned subsidiary of the Company, received funding in the form of a loan
from L'Agence Nationale de Valorisayion de la Recherche ("ANVAR"), a French
government agency, in the amount of FF5.4 million (or $.75 million at September
30, 2001) with a scheduled maturity of December 31, 2002. The utilization of the
proceeds was intended to fund research and development activities pursuant to an
agreement between ANVAR, Genta Europe and Genta (the "ANVAR Agreement"). In
October 1996, in connection with a restructuring of the Company's operations,
Genta terminated all scientific personnel of Genta Europe. ANVAR asserted in
February 1998 that Genta Europe was not in compliance with the ANVAR Agreement,
and that ANVAR might request immediate repayment of the loan. In July 1998,
ANVAR notified Genta Europe of its demand for accelerated repayment of the loan
in the amount of FF4.2 million (or $.58 million at September 30, 2001) and
subsequently notified the Company that it was liable as a guarantor on the note.
The Company does not believe that ANVAR is entitled to accelerated repayment
under the terms of the ANVAR Agreement and it is currently negotiating with
ANVAR to achieve a mutually satisfactory resolution, although there can be no
assurance thereof.

         On June 30, 1998, Marseille Amenagement, a company affiliated with the
city of Marseilles, France, filed suit in France to evict Genta Europe from its
facilities in Marseilles and to demand payment of alleged back rent due and of a
lease guarantee for nine years' rent. Following the filing of this claim and in
consideration of the request for repayment of the loan from ANVAR, Genta
Europe's Board of Directors directed the management to declare a "Cessation of
Payment." Under this procedure, Genta Europe ceased any operations and
terminated its only employee. A liquidator was appointed by the Court to take
control of any assets of Genta Europe and to make payment to creditors. In
December 1998, the Court in Marseilles dismissed the case against Genta Europe
and indicated that it had no jurisdiction against Genta Incorporated. In August
1999, Marseille Amenagement instituted legal proceedings against the Company in
the Commercial Court of Marseilles, alleging back rent and early termination
receivables aggregating FF2.5 million (or $.35 million at September 30, 2001). A
court hearing took place on June 11, 2001 but no ruling has been made as of
September 30, 2001. As of September 30, 2001, the Company has accrued a net
liability of approximately $.58 million related to the liquidated subsidiary.
Management believes that this contingency is adequately reserved, although there
can be no assurance thereof.




                                      9

<PAGE>
         PURCHASE COMMITMENTS

         During the first nine months of 2001 the Company entered into various
commitments with respect to the development and manufacture of certain
Gallium-containing compounds and, as a result, incurred R&D expense of $.67
million related to these commitments through September 30, 2001. The Company has
remaining commitments under these agreements aggregating $.37 million as of
September 30, 2001.


                                       10

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS

OVERVIEW

         Since its inception in February 1988, the Company has devoted its
principal efforts toward drug discovery and research and development. The
Company has been unprofitable to date and expects to incur substantial operating
losses for the next several years due to continued requirements for ongoing
research and development activities, preclinical and clinical testing
activities, regulatory activities, possible establishment of manufacturing
activities and a sales and marketing organization. From the period since its
inception to September 30, 2001, the Company has incurred a cumulative net loss
of approximately $180.7 million. The Company has experienced significant
quarterly fluctuations in operating results and it expects that these
fluctuations in revenues, expenses and losses will continue.

         This Quarterly Report on Form 10-Q includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, including
statements regarding the expectations, beliefs, intentions or strategies
regarding the future. Without limiting the foregoing, the words "anticipates,"
"believes," "expects," "intends," "may" and "plans" and similar expressions are
intended to identify forward-looking statements. The Company intends that all
forward-looking statements be subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements reflect the Company's views as of the date they are made with respect
to future events, but are subject to many risks and uncertainties, which could
cause the actual results of the Company to differ materially from any future
results expressed or implied by such forward-looking statements. For example,
the results obtained in pre-clinical or clinical studies may not be indicative
of results that will be obtained in future clinical trials, and delays in the
initiation or completion of clinical trials may occur as a result of many
factors. Further examples of such risks and uncertainties also include, but are
not limited to: the obtaining of sufficient financing to maintain the Company's
planned operations; timely development, receipt of necessary regulatory
approvals, and acceptance of new products; the successful application of the
Company's technology to produce new products; the obtaining of proprietary
protection for any such technology and products; the impact of competitive
products and pricing and reimbursement policies; and changing market conditions.
Additional risks and uncertainties are set forth under "Certain Trends and
Uncertainties". The Company does not undertake to update forward- looking
statements. Although the Company believes that the forward-looking statements
contained herein are reasonable, it can give no assurances that the Company's
expectations are correct.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2001 AND 2000

         REVENUES. License and royalty fees associated with worldwide
non-exclusive licensing agreements entered into during 2000 and 2001 were
recognized in the third quarter of 2001.

         COSTS AND EXPENSES. Costs and expenses for the third quarter of 2001
increased 353% to $11.396 million as compared to the third quarter of 2000. The
increase in costs and expenses related primarily to increased drug supply costs,
investigator and monitor fees for current on-going clinical studies, increased
payroll costs associated with additional headcount and increased marketing
expenses.

         RESEARCH AND DEVELOPMENT EXPENSES. Research and development expenses
for the third quarter of 2001 increased 573% to $9.150 million as compared to
the third quarter of 2000. The increase in research and development expenses is
primarily attributable to drug supply costs, investigator and monitor fees for
current on-going clinical studies, and increased payroll costs associated with
additional headcount.

         GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative
expenses for the third quarter of 2001 increased 130% to $2.060 million as
compared to the third quarter of 2000. The increase in general and
administrative expenses is primarily related to payroll costs associated with
additional headcount and increased marketing expenses.

         COMPENSATION EXPENSE RELATED TO STOCK OPTIONS. Compensation expense
related to stock options for the third quarter of 2001 decreased 27% to $.186
million as compared to the third quarter of 2000. The decrease in compensation
expense related to stock options is primarily due to the fluctuations in the
market price of the common stock underlying the stock options for the quarters
immediately preceding September 30, 2001 and September 30, 2000.


                                       11

<PAGE>
         OTHER INCOME. Net interest income increased 396% to $.953 million for
the third quarter ended September 30, 2001 as compared to the third quarter
2000, principally as a result of higher average balances of earning assets.

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2001 AND 2000

         REVENUES. License and royalty fees associated with worldwide
non-exclusive licensing agreements entered into during 2000 and 2001 were
recognized in the first nine months of 2001.

         COSTS AND EXPENSES. Costs and expenses for the first nine months of
2001 increased 107% to $30.948 million as compared to the first nine months of
2000. The increase in costs and expenses related primarily to increased drug
supply costs, investigator and monitor fees for current on-going clinical
studies, increased payroll costs associated with additional headcount and
increased marketing expenses.

         RESEARCH AND DEVELOPMENT EXPENSES. Research and development expenses
for first nine months of 2001 increased 508% to $23.786 million as compared to
the first nine months of 2000. The increase in research and development expenses
is primarily attributable to drug supply costs, investigator and monitor fees
for current on-going clinical studies, and increased payroll costs associated
with additional headcount.

         As a result of the initiation of Phase 3 clinical trials for melanoma,
chronic lymphocytic leukemia (CLL) and multiple myeloma, it is anticipated that
future research and development expenses will continue to escalate at an
increasing rate as the development program for GenasenseTM expands and more
patients are enrolled in clinical trials. Furthermore, the Company is pursuing
other opportunities for new product development candidates which pursuits, if
successful, will require additional research and development expenses. There can
be no assurance that the trials will proceed in this manner or that the Company
will initiate new development programs. On-going Phase 3 clinical trials and
related drug supply costs were minimal for the nine months ended September 30,
2000.

         GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative
expenses for first nine months of 2001 increased 105% to $5.582 million as
compared to the first nine months of 2000. The increase is primarily related to
payroll costs associated with additional headcount and increased marketing
expenses.

         PROMEGA SETTLEMENT. During the first quarter of 2001, the Company
agreed to resolve the matter more fully discussed in Note 2, and in connection
therewith, the Company agreed to restructure its $1.2 million promissory note
receivable to provide for a $.2 million non-interest bearing note due upon final
resolution of certain environmental issues related to JBL as more fully
discussed in Note 8, and forgiveness of all accrued interest. The transaction
resulted in a non-recurring charge of $1.0 million for the quarter ended March
31, 2001.

         COMPENSATION EXPENSE RELATED TO STOCK OPTIONS. Compensation expense
related to stock options for the first nine months of 2001 decreased 93% to
$.580 million as compared to the first nine months of 2000. The decrease in
compensation expense related to stock options is primarily attributable to the
acceleration of stock options for retiring Board members during the first
quarter of 2000.

         EQUITY IN NET INCOME OF JOINT VENTURE. Genta recognized approximately
$.502 million as its equity in net income of the joint venture for the nine
months ended September 30, 2000, as more fully discussed in Note 5.

         OTHER INCOME. Net interest income increased 353% to $2.061 million for
the first nine months of 2001 as compared to the first nine months of 2000,
principally as a result of higher average balances of earning assets.

LIQUIDITY AND CAPITAL RESOURCES

         Since its inception, the Company has financed its operations primarily
from private and public offerings of its equity securities. Cumulative cash
provided from these offerings totaled approximately $176 million through
September 30, 2001, including net proceeds of $40.0 million received in 2000 and
$10.4 million received in 1999. At September


                                       12
<PAGE>

30, 2001, the Company had cash, cash equivalents and short-term investments
totaling $34.2 million compared to approximately $50.2 million at December 31,
2000. Management believes the Company will have sufficient liquidity to maintain
its present level of operations into the second quarter of 2002.

         The Company's principal expenditures relate to its research and
development activities, which includes the Company's current and on-going
clinical trials. The Company expects this to continue at an increasing rate
until its lead anti-cancer drug, GenasenseTM, is approved for commercialization.

         Certain parties with whom the Company has agreements have claimed
default and, should the Company be obligated to pay these claims or should the
Company engage legal services to defend or negotiate its positions or both, its
ability to continue operations could be significantly reduced or shortened. See
"MD&A -- Certain Trends and Uncertainties -- Claims of Genta's Default Under
Various Agreements."

         The Company anticipates that significant additional sources of
financing, including equity financing, will be required in order for the Company
to continue its planned operations beyond the second quarter of 2002. The
Company also anticipates seeking additional product development opportunities
from external sources. Such acquisitions may consume cash reserves or require
additional cash or equity. The Company's working capital and additional funding
requirements will depend upon numerous factors, including: (i) the progress of
the Company's research and development programs; (ii) the timing and results of
preclinical testing and clinical trials; (iii) the level of resources that the
Company devotes to sales and marketing capabilities; (iv) technological
advances; (v) the activities of competitors; and (vi) the ability of the Company
to establish and maintain collaborative arrangements with others to fund certain
research and development efforts, to conduct clinical trials, to obtain
regulatory approvals and, if such approvals are obtained, to manufacture and
market products. See "MD&A -- Certain Trends and Uncertainties -- Our Business
Will Suffer if We Fail to Obtain Timely Funding."

         Management believes that successful development of the Company's
Gallium products franchise may yield substantial clinical and competitive
advantages. Accordingly, during 2001 the Company entered into various
commitments with respect to the development and manufacture of certain
Gallium-containing compounds as more fully described in Note 8 to the condensed
consolidated financials statements.

         If the Company successfully secures sufficient levels of collaborative
revenues and other sources of financing, it expects to use such financing to
continue and expand its ongoing research and development activities, preclinical
and clinical testing activities, the manufacturing and/or market introduction of
potential products and expansion of its administrative activities.

RECENT ACCOUNTING PRONOUNCEMENTS

         See Note 1 to the condensed consolidated financials statements.

CERTAIN TRENDS AND UNCERTAINTIES

         In addition to the other information contained in this Quarterly Report
on Form 10-Q, the following factors should be considered carefully.


   The Company may be unsuccessful in our efforts to commercialize our
pharmaceutical products, such as GaniteTM and GenasenseTM.

         The commercialization of our pharmaceutical products involves a number
of significant challenges. In particular, our ability to commercialize products,
such as GaniteTM and GenasenseTM, depends, in large part, on the success of our
clinical development programs, and our sales and marketing efforts to
physicians, patients and third-party payors. A number of factors could impact
these efforts, including our ability to demonstrate clinically that our products
have utility beyond current indications, delays by regulatory authorities in
granting marketing approvals, our limited financial resources and sales and
marketing experience relative to our competitors, perceived differences between
our products and those of our competitors, the availability and level of
reimbursement of our products by third-party payors,


                                       13

<PAGE>

incidents of adverse reactions, side effects or misuse of our products and the
unfavorable publicity that could result, or the occurrence of manufacturing,
supply or distribution disruptions. In particular, the Company has said that it
intends to be a direct marketer of its products in the United States. Our
inability to build a sales force capable of marketing our pharmaceutical
products will adversely affect our sales and limit the commercial success of our
products.

         Ultimately, our efforts may not prove to be as effective as the efforts
of our competitors. In the United States and elsewhere, our products face
significant competition in the marketplace. The conditions that our products
treat, and some of the other disorders for which we are conducting additional
studies, are currently treated with several drugs, many of which have been
available for a number of years or are available in inexpensive generic forms.
Thus, we will need to demonstrate to physicians, patients and third party payors
that the cost of our products is reasonable and appropriate in light of their
safety and efficacy, the price of competing products and the related health care
benefits to the patient. Even if we are able to increase sales over the next
several years, we cannot be sure that such sales and other revenue will reach a
level at which we will attain profitability.

   Our business will suffer if we fail to obtain timely funding.

         Our Company's operations to date have consumed substantial amounts of
cash. Based on our current operating plan, we believe that our available
resources, including the proceeds from two private offerings in September and
November 2000, will be adequate to satisfy our capital needs into the second
quarter of 2002. Our future capital requirements will depend on the results of
our research and development activities, pre-clinical studies and bioequivalence
and clinical trials, competitive and technological advances, and regulatory
processes of the FDA and other regulatory authority. In order to commercialize
our products, we will need to raise additional financing. We may seek additional
financing through public and private resources, including debt or equity
financing, or through collaborative or other arrangements with research
institutions and corporate partners. We may not be able to obtain adequate funds
for our operations from these sources when needed or on acceptable terms. If we
raise additional capital by issuing equity, or securities convertible into
equity, the ownership interest of existing Genta stockholders will be subject to
further dilution and share prices may decline. If we are unable to raise
additional financing, we will need to do the following:

         -        delay, scale back or eliminate some or all of our research and
                  product development programs;
         -        license third parties to commercialize products or
                  technologies that we would otherwise seek to develop
                  ourselves;
         -        sell Genta to a third party;
         -        to cease operations; or
         -        declare bankruptcy.

   Many of our products are in an early stage of development.

         Most of our resources have been dedicated to applying molecular biology
and medicinal chemistry to the research and development of potential antisense
pharmaceutical products based upon oligonucleotide technology. While we have
demonstrated the activity of antisense oligonucleotide technology in model
systems in vitro in animals, only one of these potential antisense
oligonucleotide products, GenasenseTM, has been tested in humans. Results
obtained in preclinical studies or early clinical investigations are not
necessarily indicative of results that will be obtained in extended human
clinical trials. Our products may prove to have undesirable and unintended side
effects or other characteristics that may prevent our obtaining FDA or foreign
regulatory approval for any indication. In addition, it is possible that
research and discoveries by others will render our oligonucleotide technology
obsolete or noncompetitive.

   Clinical trials are costly and time consuming and are subject to delays.

         Clinical trials are very costly and time-consuming. How quickly we are
able to complete a clinical study depends upon several factors, including the
size of the patient population, how easily patients can get to the site of the
clinical study, and the criteria for determining which patients are eligible to
join the study. Delays in patient


                                       14


<PAGE>
enrollment could delay completion of a clinical study and increase its costs,
and could also delay the commercial sale of the drug that is the subject of the
clinical trial.

         Our commencement and rate of completion of clinical trials also may be
delayed by many other factors, including the following:

         -        inability to obtain sufficient quantities of materials used
                  for clinical trials;
         -        inability to adequately monitor patient progress after
                  treatment;
         -        unforeseen safety issues;
         -        the failure of the products to perform well during clinical
                  trials; and
         -        government or regulatory delays.

   We cannot market and sell our products in the United States or in other
countries if we fail to obtain the necessary regulatory approvals.

         The United States Food and Drug Administration and comparable agencies
in foreign countries impose substantial premarket approval requirements on the
introduction of pharmaceutical products through lengthy and detailed preclinical
and clinical testing procedures and other costly and time-consuming procedures.
Satisfaction of these requirements typically takes several years or more
depending upon the type, complexity and novelty of the product. While limited
trials of our products have produced favorable results, we cannot apply for FDA
approval to market any of our products under development until the product
successfully completes its preclinical and clinical trials. Several factors
could prevent successful completion or cause significant delays of these trials,
including an inability to enroll the required number of patients or failure to
demonstrate adequately that the product is safe and effective for use in humans.
If safety concerns develop, the FDA could stop our trials before completion. If
we are not able to obtain regulatory approvals for use of our products under
development, or if the patient populations for which they are approved are not
sufficiently broad, the commercial success of our products could be limited.

   We may be unable to obtain or enforce patents and other proprietary rights
to protect our business.

         Our success will depend to a large extent on our ability to (1) obtain
U.S. and foreign patent or other proprietary protection for our technologies,
products and processes, (2) preserve trade secrets and (3) operate without
infringing the patent and other proprietary rights of third parties. Legal
standards relating to the validity of patents covering pharmaceutical and
biotechnological inventions and the scope of claims made under such patents are
still developing. There is no consistent policy regarding the breadth of claims
allowed in biotechnology patents. As a result, our ability to obtain and enforce
patents that protect our drugs is highly uncertain and involves complex legal
and factual questions.

         We have more than 75 U.S. and international patents to aspects of our
technology, which includes novel compositions of matter, methods of large-scale
synthesis and methods of controlling gene expression. We may not receive any
issued patents based on pending or future applications. Our issued patents may
not contain claims sufficiently broad to protect us against competitors with
similar technology. Additionally, our patents, our partners' patents and patents
for which we have license rights may be challenged, narrowed, invalidated or
circumvented. Furthermore, rights granted under our patents may not cover
commercially valuable drugs or processes and may not provide us with any
competitive advantage.

         We may have to initiate arbitration or litigation to enforce our patent
and license rights. If our competitors file patent applications that claim
technology also claimed by us, we may have to participate in interference or
opposition proceedings to determine the priority of invention. An adverse
outcome could subject us to significant liabilities to third parties and require
us to cease using the technology or to license the disputed rights from third
parties. We may not be able to obtain any required licenses on commercially
acceptable terms or at all.


                                       15


<PAGE>
         The cost to us of any litigation or proceeding relating to patent
rights, even if resolved in our favor, could be substantial. Some of our
competitors may be able to sustain the costs of complex patent litigation more
effectively than we can because of their substantially greater resources.
Uncertainties resulting from the initiation and continuation of any pending
patent or related litigation could have a material adverse effect on our ability
to compete in the marketplace.

   We rely on our contractual collaborative arrangements with research
institutions and corporate partners for development and commercialization of our
products.

         Our business strategy depends in part on our continued ability to
develop and maintain relationships with leading academic and research
institutions and independent researchers. The competition for such relationships
is intense, and we can give no assurances that we will be able to develop and
maintain such relationships on acceptable terms. We have entered into a number
of collaborative relationships relating to specific disease targets and other
research activities in order to augment our internal research capabilities and
to obtain access to specialized knowledge and expertise. The loss of any of
these collaborative relationships could have a material adverse effect on our
business.

         Similarly, strategic alliances with corporate partners, primarily
pharmaceutical and biotechnology companies, may help us develop and
commercialize drugs. Various problems can arise in strategic alliances. A
partner responsible for conducting clinical trials and obtaining regulatory
approval may fail to develop a marketable drug. A partner may decide to pursue
an alternative strategy or alternative partners. A partner that has been granted
marketing rights for a certain drug within a geographic area may fail to market
the drug successfully. Consequently, strategic alliances that we may enter into
in the future may not be scientifically or commercially successful. We may be
unable to negotiate advantageous strategic alliances in the future. The absence
of, or failure of, strategic alliances could harm our efforts to develop and
commercialize our drugs.

   The raw materials for our products are produced by a limited number of
suppliers.

         The raw materials that we require to manufacture our drugs,
particularly oligonucleotides, are available from only a few suppliers, namely
those with access to our patented technology. If these few suppliers cease to
provide us with the necessary raw materials or fail to provide us with adequate
supply of materials at an acceptable price and quality, we could be materially
adversely affected.

   The successful commercialization of our products will depend on obtaining
coverage and reimbursement for use of our products from third-party payors.

         Our ability to commercialize drugs successfully will depend in part on
the extent to which various third parties are willing to reimburse patients for
the costs of our drugs and related treatments. These third parties include
government authorities, private health insurers, and other organizations, such
as health maintenance organizations. Third-party payors often challenge the
prices charged for medical products and services. Accordingly, if less costly
drugs are available, third-party payors may not authorize or may limit
reimbursement for our drugs, even if they are safer or more effective than the
alternatives. In addition, the federal government and private insurers have
considered ways to change, and have changed, the manner in which health care
services are provided and paid for in the United States. In particular, these
third-party payors are increasingly attempting to contain health care costs by
limiting both coverage and the level of reimbursement for new therapeutic
products. In the future, it is possible that the government may institute price
controls and further limits on Medicare and Medicaid spending. These controls
and limits could affect the payments we collect from sales of our products.
Internationally, medical reimbursement systems vary significantly, with some
medical centers having fixed budgets, regardless of levels of patient treatment,
and other countries requiring application for, and approval of, government or
third-party reimbursement. Even if we or our partners succeed in bringing
therapeutic products to market, uncertainties regarding future health care
policy, legislation and regulation, as well as private market practices, could
affect our ability to sell our products in commercially acceptable quantities at
profitable prices.



                                       16


<PAGE>
   We could become involved in time-consuming and expensive patent litigation
and adverse decisions in patent litigation could cause us to incur additional
costs and experience delays in bringing new drugs to market.

         The pharmaceutical and biotechnology industries have been characterized
by time-consuming and extremely expensive litigation regarding patents and other
intellectual property rights. We may be required to commence, or may be made a
party to, litigation relating to the scope and validity of our intellectual
property rights, or the intellectual property rights of others. Such litigation
could result in adverse decisions regarding the patentability of our inventions
and products, or the enforceability, validity, or scope of protection offered by
our patents. Such decisions could make us liable for substantial money damages,
or could bar us from the manufacture, use, or sale of certain products,
resulting in additional costs and delays in bringing drugs to market. We may not
have sufficient resources to bring any such proceedings to a successful
conclusion. It may be that entry into a licensing arrangement would allow us to
avoid any such proceedings. We may not be able, however, to enter into any such
licensing arrangement on terms acceptable to us, or at all.

         We also may be required to participate in interference proceedings
declared by the U.S. Patent and Trademark Office and in International Trade
Commission proceedings aimed at preventing the importing of drugs that would
compete unfairly with our drugs. Such proceedings could cause us to incur
considerable costs.

   Our business exposes us to potential product liability which may have a
negative effect on our financial performance.

         The administration of drugs to humans, whether in clinical trials or
commercially, exposes us to potential product and professional liability risks,
which are inherent in the testing, production, marketing and sale of human
therapeutic products. Product liability claims can be expensive to defend and
may result in large judgments or settlements against us, which could have a
negative effect on our financial performance. We maintain product liability
insurance (subject to various deductibles), but our insurance coverage may not
be sufficient to cover claims. Furthermore, we cannot be certain that we will
always be able to purchase sufficient insurance at an affordable price. Even if
a product liability claim is not successful, the adverse publicity and time and
expense of defending such a claim may interfere with our business.

   If we cease doing business and liquidate our assets, we are required to
distribute proceeds to holders of our preferred stock before we distribute
proceeds to holders of our common stock.

         In the event of a dissolution or liquidation of Genta, holders of Genta
common stock will not receive any proceeds until holders of 261,200 outstanding
shares of Genta Series A preferred stock are paid a $13.1 million liquidation
preference.

   There currently exist certain interlocking relationships and potential
conflicts of interest.

         Certain of our affiliates, Aries Select I, LLC, Aries Select II, LLC,
and Aries Select, LTD (together the "Aries Funds"), have the contractual right,
which expires January 1, 2002, to appoint a majority of the members of the Board
of Directors of the Company. Paramount Capital Asset Management, Inc. ("PCAM")
is the investment manager of the Aries Funds. The Aries Funds have the right to
convert and exercise their securities into a significant portion of the
outstanding common stock. Dr. Lindsay A. Rosenwald, the Chairman and sole
stockholder of PCAM, is also the Chairman of Paramount Capital, Inc. and of
Paramount Capital Investments LLC ("PCI"), a New York-based merchant banking and
venture capital firm specializing in biotechnology companies. PCAM, PCI and its
affiliates collectively control approximately 40% of the Company's common stock
when calculated on a fully diluted basis. In the regular course of its business,
PCI identifies, evaluates and pursues investment opportunities in biomedical and
pharmaceutical products, technologies and companies. Generally, the law requires
that any transactions between Genta and any of its affiliates be on terms that,
when taken as a whole, are substantially as favorable to us as those then
reasonably obtainable from a person who is not an affiliate in an arms-length
transaction. Nevertheless, our affiliates including PCAM and PCI are not
obligated pursuant to any agreement or understanding with the Company to make
any additional products or technologies available to the Company, nor can there
be any assurance, and we do not expect and you should not expect, that any
biomedical or pharmaceutical product or technology developed by any affiliate in
the future will be made available to us. In addition, some of our officers and
directors of the Company or certain of any officers or directors of the Company
hereafter appointed may from time to time serve as officers or directors of
other biopharmaceutical or biotechnology companies. We cannot assure you that
these other companies will not have interests in conflict with ours.


                                       17

<PAGE>

   Concentration of ownership of our stock could lead to a delay or prevent a
change of control.

         Our directors, executive officers and principal stockholders and their
affiliates own a significant percentage of our outstanding common stock and
preferred stock. They also have, through the exercise of options and warrants,
the right to acquire even more common stock and preferred stock. As a result,
these stockholders, if acting together, have the ability to influence the
outcome of corporate actions requiring stockholder approval. This concentration
of ownership may have the effect of delaying or preventing a change in control
of Genta.

   Anti-takeover provisions in our certificate of incorporation and Delaware
law may prevent our stockholders from receiving a premium for their shares.

         Our certificate of incorporation and by-laws include provisions that
could discourage takeover attempts and impede stockholders ability to change
management. The approval of 66-2/3% of our voting stock is required to approve
certain transactions and to take certain stockholder actions, including the
amendment of the by-laws and the amendment, if any, of the anti-takeover
provisions contained in our certificate of incorporation.

   We anticipate that we will incur additional losses.

         The Company has not been profitable to date, incurring substantial
operating losses associated with ongoing research and development activities,
preclinical testing, clinical trials and manufacturing activities. From the
period since its inception to September 30, 2001, the Company has incurred a
cumulative net loss of $180.7 million. We expect to continue to incur losses
until such time as product and other revenue exceed expenses of operating our
business. While we seek to attain profitability, we cannot be sure that we will
ever achieve product and other revenue sufficient for us to attain this
objective.

   Claims of Genta's Default Under Various Agreements.

         During 1995, Genta Europe, a wholly-owned subsidiary of the Company,
received funding in the form of a loan from ANVAR, a French government agency,
in the amount of FF5.4 million (or $.75 million at September 30, 2001) with a
scheduled maturity of December 31, 2002. The utilization of the proceeds was
intended to fund research and development activities pursuant to the ANVAR
Agreement. In October 1996, in connection with a restructuring of the Company's
operations, Genta terminated all scientific personnel of Genta Europe. ANVAR
asserted in February 1998, that Genta Europe was not in compliance with the
ANVAR Agreement, and that ANVAR might request immediate repayment of the loan.
In July 1998, ANVAR notified Genta Europe of its demand for accelerated
repayment of the loan in the amount of FF4.2 million (or $.58 million at
September 30, 2001) and subsequently notified the Company that it was liable as
a guarantor on the note. The Company does not believe that ANVAR is entitled to
accelerated repayment under the terms of the ANVAR Agreement and it is currently
negotiating with ANVAR to achieve a mutually satisfactory resolution, although
there can be no assurance thereof.

         On June 30, 1998, Marseille Amenagement, a company affiliated with the
city of Marseilles, France, filed suit in France to evict Genta Europe from its
facilities in Marseilles and to demand payment of alleged back rent due and of a
lease guarantee for nine years' rent. Following the filing of this claim and in
consideration of the request for repayment of the loan from ANVAR, Genta
Europe's Board of Directors directed the management to declare a "Cessation of
Payment." Under this procedure, Genta Europe ceased any operations and
terminated its only employee. A liquidator was appointed by the Court to take
control of any assets of Genta Europe and to make payment to creditors. In
December 1998, the Court in Marseilles dismissed the case against Genta Europe
and indicated that it had no jurisdiction against Genta Incorporated. In August
1999, Marseille Amenagement instituted legal proceedings against the Company in
the Commercial Court of Marseilles, alleging back rent and early termination
receivables aggregating FF2.5 million (or $.35 million at September 30, 2001). A
court hearing took place on June 11, 2001 but no ruling has been made as of
September 30, 2001. As of September 30, 2001, the Company has accrued a net
liability of approximately $.58 million related to the liquidated subsidiary.
Management believes that this contingency is adequately reserved, although there
can be no assurance thereof.

                                       18

<PAGE>
   Dividends.

         The Company has never paid cash dividends on its common stock and does
not anticipate paying any such dividends in the foreseeable future. As a result
of the mandatory conversion of Series D Convertible Preferred Stock in June
2000, no dividends were required to be paid beyond January 29, 2000. The Company
currently intends to retain its cash for reinvestment in its business.

   The Company is dependent on key executives and scientists.

         The Company's success is highly dependent on the hiring and retention
of key personnel and scientific staff. The loss of key personnel or the failure
to recruit necessary additional personnel or both is likely further to impede
the achievement of development objectives. There is intense competition for
qualified personnel in the areas of the Company's activities, and there can be
no assurance that Genta will be able to attract and retain the qualified
personnel necessary for the development of its business.

   Volatility of Stock Price; Market Overhang from Outstanding Convertible
Securities and Warrants.

         The market price of the Company's common stock, like that of the common
stock of many other biopharmaceutical companies, has been highly volatile and
may be so in the future. Factors such as, among other things, the results of
pre-clinical studies and clinical trials by the Company or its competitors,
other evidence of the safety or efficacy of products of the Company or its
competitors, announcements of technological innovations or new therapeutic
products by the Company or its competitors, governmental regulation,
developments in patent or other proprietary rights of the Company or its
respective competitors, including litigation, fluctuations in the Company's
operating results, and market conditions for biopharmaceutical stocks in general
could have a significant impact on the future price of the common stock. As of
November 5, 2001, the Company had 63,151,057 shares of common stock outstanding.
Future sales of shares of common stock by existing stockholders, holders of
preferred stock who might convert such preferred stock into common stock, and
option and warrant holders also could adversely affect the market price of the
common stock.

         No predictions can be made of the effect that future market sales of
the shares of common stock underlying the convertible securities and warrants
referred to under the caption "MD&A -- Certain Trends and Uncertainties -- If we
cease doing business and liquidate our assets, we are required to distribute
proceeds to holders of our preferred stock before we distribute proceeds to
holders of our common stock," or the availability of such securities for sale,
will have on the market price of the common stock prevailing from time to time.

         Sales of substantial amounts of common stock, or the perception that
such sales might occur, could adversely affect prevailing market prices.




                                       19


<PAGE>
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

         The Company does not utilize financial instruments for trading purposes
and holds no derivative financial instruments, which could expose the Company to
significant market risk. The Company's primary market risk exposure with regard
to financial instruments is to changes in interest rates, which would impact
interest income earned on such instruments.









                                       20

<PAGE>
PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

         In October 1996, JBL retained a chemical consulting firm to advise it
with respect to an incident of soil and groundwater contamination (the "Spill").
Sampling conducted at the JBL facility revealed the presence of chloroform and
perchloroethylenes ("PCEs") in the soil and groundwater at this site. A
semi-annual groundwater-monitoring program is being conducted under the
supervision of the California Regional Water Quality Control Board ("the Water
Board") for the purpose of determining whether the levels of chloroform and PCEs
have decreased over time. In April 2001, the Company requested closure of this
matter from the Water Board as the current sampling results indicated that PCEs
and chloroform have decreased in all of the monitoring sites. The Water Board
has instructed the Company to remove these monitoring wells, which is the last
step before final site closure. The Company is currently in the process of
having these monitoring wells removed. The Company has agreed to indemnify
Promega with respect to this matter and, in the opinion of management, has
adequately accrued to cover remedial expenses as of September 30, 2001.
Management also believes that any residual expense stemming from further
investigation or remediation of this matter will not have a material adverse
effect on the business of the Company, although there can be no assurance
thereof.

         JBL received notice on October 16, 1998 from Region IX of the
Environmental Protection Agency (the "EPA") that it had been identified as a
potentially responsible party ("PRP") at the Casmalia Disposal Site located in
Santa Barbara, California. The EPA has designated JBL as a de minimis PRP and
the Company expects to receive a revised settlement proposal from the EPA later
this year. While the terms of the EPA settlement have not been finalized,
management believes that such terms shall provide for standard contribution
protection and release provisions. The Company has agreed to indemnify Promega
with respect to this matter and management believes that any residual expense
stemming from further investigation or remediation of this matter will not have
a material adverse effect on the business of the Company, although there can be
no assurance thereof.

         During 1995, Genta Europe, a wholly-owned subsidiary of the Company,
received funding in the form of a loan from ANVAR, a French government agency,
in the amount of FF5.4 million (or $.75 million at September 30, 2001) with a
scheduled maturity of December 31, 2002. The utilization of the proceeds was
intended to fund research and development activities pursuant to the ANVAR
Agreement. In October 1996, in connection with a restructuring of the Company's
operations, Genta terminated all scientific personnel of Genta Europe. ANVAR
asserted in February 1998, that Genta Europe was not in compliance with the
ANVAR Agreement, and that ANVAR might request immediate repayment of the loan.
In July 1998, ANVAR notified Genta Europe of its demand for accelerated
repayment of the loan in the amount of FF4.2 million (or $.58 million at
September 30, 2001) and subsequently notified the Company that it was liable as
a guarantor on the note. The Company does not believe that ANVAR is entitled to
accelerated repayment under the terms of the ANVAR Agreement and it is currently
negotiating with ANVAR to achieve a mutually satisfactory resolution, although
there can be no assurance thereof.

         On June 30, 1998, Marseille Amenagement, a company affiliated with the
city of Marseilles, France, filed suit in France to evict Genta Europe from its
facilities in Marseilles and to demand payment of alleged back rent due and of a
lease guarantee for nine years' rent. Following the filing of this claim and in
consideration of the request for repayment of the loan from ANVAR, Genta
Europe's Board of Directors directed the management to declare a "Cessation of
Payment." Under this procedure, Genta Europe ceased any operations and
terminated its only employee. A liquidator was appointed by the Court to take
control of any assets of Genta Europe and to make payment to creditors. In
December 1998, the Court in Marseilles dismissed the case against Genta Europe
and indicated that it had no jurisdiction against Genta Incorporated. In August
1999, Marseille Amenagement instituted legal proceedings against the Company in
the Commercial Court of Marseilles, alleging back rent and early termination
receivables aggregating FF2.5 million (or $.35 million at September 30, 2001). A
court hearing took place on June 11, 2001 but no ruling has been made as of
September 30, 2001. As of September 30, 2001, the Company has accrued a net
liability of approximately $.58 million related to the liquidated subsidiary.
Management believes that this contingency is adequately reserved, although there
can be no assurance thereof.




                                       21


<PAGE>

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

                  None.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

                  (a)      Exhibits.

                           None.

                  (b)      Reports on Form 8-K.

                           None.




                                       22


<PAGE>


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.




                          GENTA INCORPORATED
                          (Registrant)





                          By:      /s/ Raymond P. Warrell, Jr., M.D.
                                   -------------------------------------------
                          Name:    Raymond P. Warrell, Jr., M.D.
                          Title:   Chairman, President, Chief Executive Officer
                                   and Principal Executive Officer







                          By:      /s/ Alfred J. Fernandez
                                   -------------------------------------------
                          Name:    Alfred J. Fernandez
                          Title:   Executive Vice President, Chief Financial
                                   Officer and Principal Accounting Officer


 Date: November 7, 2001




                                       23